Type Public Industry Biotechnology Founder Richard Garr | Traded as NASDAQ: CUR Website www.neuralstem.com Founded 1996 | |
 | ||
Key people Richard Garr : Founder; Richard J. Daly: President and CEO; Products Stem Cell Research (currently in human trials) Stock price CUR (NASDAQ) US$ 5.50 +0.05 (+0.92%)24 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Rockville, Maryland, United States | ||
Neuralstem Inc. is a biotechnology company headquartered in Rockville, Maryland that specializes in developing commercial-scale production of multiple types of central nervous system stem cells.
Company information
Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem’s NSI-566 spinal cord-derived stem cell therapy Phase II clinical trials for ALS concluded final surgeries in July 2014. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy. In addition to ALS, the company is also targeting major CNS conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The company has received approvals from the FDA and the Institutional Review Board of University of California, San Diego, to commence a Phase I safety trial in chronic spinal cord injury.
Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate neurons, possibly reversing pathologies associated with certain CNS conditions. The company has completed Phase Ia and Ib trials evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD), and is expecting to launch a Phase II NSI-189/MDD study in 2015. Additional indications might include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).